50 results about "Chrysophanic acid" patented technology

The invention discloses the applications of compounds, selected from quercetin, chrysophanic acid, digicitrine, formononetin, honokiol, berberine, kaempferol, bergenin, deoxyepinephrine and licochalcone A, as well as derivatives thereof, in preparation of medicines applied to methods that are used for promoting stem cell proliferation, delaying senescence of stem cells, promoting differentiation of the stem cells into osteoblasts, chondrocytes and adipocytes, enhancing the vascularization capability of the stem cells and / or improving exercise tolerance of mice. The invention also discloses that the compounds can be combined with vitamin C for application.

The present invention discloses compositions of rheinic acid or rheinic acid compound as shown in the general expression and nitrogen-containing organic base or basic amino acid combined through intermolecular force. The present invention discloses the preparation process of the compositions and their application in preparing medicine for treating diabetic nephrosis.

The invention belongs to the field of medical technology, in particular relating to an organic acid platinum salt and the preparation method thereof and the application to the preparation of anti-cancer drugs. The invention obtains the Pt(C6H14N2)Cl2 or Pt(NH3)2Cl2 through the dissolution and reaction of trans-cyclohexanediamine or ammonia and potassium chloroplatinite in water at indoor temperature; the products of the organic platinum salt are obtained through the ways that the Pt(C6H14N2)Cl2 or the Pt(NH3)2Cl2 is suspended in water, and silver nitrate is added into the water and the Pt(C6H14N2)Cl2 or the Pt(NH3)2Cl2 reacts with the silver nitrate at indoor temperature, and the formed AgCl is precipitated, filtered and removed, and the NaOH solution of the organic acid is added into the filtrates and reacts with the filtrates overnight at indoor temperature; wherein, the organic acid is ursolic acid, asiatic acid, betulinic acid, lucidenic acid C, sennoside B or rhein, etc. The anti-tumor effect experiments on mice loading Lewis lung cancer show that the organic acid platinum salt of the invention has the significant anti-tumor effects, so the organic platinum salt can be used for preparing anti-cancer drugs.

The present invention relates to a method of using an anthraquinone derivative namely 9,10-Dihyro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, or known as Rhein, for treating chronic pancreatitis induced fibrosis of the pancreas. More particularly, the present invention relates to a method of using Rhein, its derivatives and / or chemical variants as an anti-fibrotic agent. The present invention particularly relates to the suppression of pancreatic stellate cell activation for the management of chronic inflammatory, fibrotic and tumorigenic pathologies in the pancreas.

The invention relates to a process of preparing chromatographic fixed phase using functional coupling agent by means of secondset reaction, which comprises three steps: (1) preparing gamma-amino propyl bonding silica gel prosoma; (2) adding excess chlorinated sulfoxide into emodic acid for ereaction under regurgitation condition for 2 hours, vacuum boiling left chlorinated sulfoxide and getting emodic acid chloride; (3) proceeding reaction under regurgitation and stirring condition with protective nitrogen for 10 hours with prosoma and emodic acid chloride, taking waterless toluene as disslovant and triethylamine as catalyst; extracting, washing, floating and fdrying solid and preparing emodic acid bonding silica gel fixed phase. The invention is chartacterized by simple process, low production cost, high concentration of bonded ligand on surface of said fixed phase, and hardness for bacteria growth because of antibiotic action of emodic acid. The emodic acid bonded silica gel fixed phase is suitable for high efficiency liquid chromatography, microcylinder liquid chromatography and electrochromatography analysis and separation. It can also suit to be used as relative enriched material.

The invention relates to a medicinal composition for treating renal diseases and the pharmaceutical use of the medicinal composition. The composition contains rhein, physcion, emodin glucoside, chrysophanol glucoside, salvianic acid, salvianolic acid B, hydroxysafflor yellow A, astragaloside, astragalus polysaccharide, salvianolic acid A, calycosin-7-glucoside, physcion glucoside, rosmarinic acid, carthamin yellow A, salvianolic acid D, salvianolic acid H, protocatechuic aldehyde, caffeic acid and gallic acid, wherein the chrysophanol glucoside is chrysophanol monoglucoside, the emodin glucoside is emodin monoglucoside, and the physcion glucoside is physcion monoglucoside. The composition can also contain C11H9N6O4, C17H14O4, C21H20O9, C19H32O12, C30H36O15 and C30H44O15. The composition is a preparation in a solid form, a liquid form, a gas form or a semisolid form, and a great number of experiments show that the composition can be used for treating renal diseases, renal failure, nephrotic syndromes, cardiovascular and cerebrovascular diseases, neoplastic diseases and the like.

A process for preparing diacetylchrysophanic acid from the extract of rhubab (chrysophanic acid, chrysophanol, or aloe-emodin) includes such steps as acetylating, oxidizing, removing Cr, ammonizing, conversing, acidifying, recrystallizing and drying. Said product can be used for treating osteoarthritis.

The invention discloses a making method of rhein, which is characterized by the following: extracting rhein from plant rhubarb horsetails; adopting residual drug slag as raw material; saving cost; protecting environment without constructing mother ring; reducing reciprocal operation in other synthetic routes; simplifying disposing course; improving total receiving rate at 56%.

The invention discloses a series of diacerhein aminophosphonate derivatives, and a synthetic method and applications thereof. The synthetic method of the diacerhein aminophosphonate derivatives comprises: taking diacerhein and an alpha-aminophosphonate as raw materials, dissolving in a polar solvent, in the presence of a catalyst HOBT and a condensing agent EDAC, reacting completely; and adding trichloromethane into the reaction liquid, washing with water, applying the organic layer to silica gel for column chromatography, eluting with a mixed solvent of ethyl acetate and petroleum ether with a volume ratio of 1:6-100 to obtain the corresponding derivative. The diacerhein aminophosphonate derivatives have the structural general formula (I) as shown in the description, wherein R is p-bromophenyl, o-bromophenyl, m-bromophenyl, p-fluorophenyl, o-fluorophenyl, p-chlorophenyl, m-chlorophenyl, o-chlorophenyl, m-methoxyphenyl, o-methoxyphenyl, phenyl, naphthyl, p-methoxyphenyl, m-methylphenyl, p-methylphenyl, m-fluorophenyl or anthryl.

The invention discloses semen cassiae oral liquid capable of relaxing bowels and lubricating intestines. The oral liquid is used for treating constipation caused by gastrointestinal heat, intestinal dry and body fluid deficiency. The oral liquid comprises, by weight, 10-50 parts of semen cassiae, 10-20 parts of scutellaria baicalensis, 10-20 parts of root of rehmannia, 10-20 parts of semen plantaginis, 10-20 parts of bighead atractylodes rhizome, 10-20 parts of radix scrophulariae, 10-20 parts of fructus aurantii, 10-20 parts of lotus leaves, 10-20 parts of fructus cannabis, 10-20 parts of gynostemma pentaphylla, 10-20 parts of mulberries, 10-20 parts of cape jasmine, 10-20 parts of curcuma aromatica, 10-20 parts of angelica sinensis, 10-20 parts of pericarpium citri reticulatae, 10-20 parts of indigo naturalis and 10-20 parts of mangnolia officinalis. The semen cassiae has the functions of clearing liver, improving vision, relaxing bowels, lubricating intestines, reducing fat and losing weight. Besides saccharides, protein and fat, the oral liquid further contains steroids, chrysophanic acid, rheum emodin and microelements, such as Fe, Zn, Mn, Cu, Ni, Co and Mo, which are essential to human bodies. The semen cassiae tastes bitter, and the taste of the semen cassiae is not easy for people to accept. By means of the oral liquid, the functions of reducing fat, losing weight, relaxing bowels and lubricating intestines are well achieved.

The invention discloses a sphalerite flotation composite inhibitor and application thereof, and belongs to the technical field of sphalerite flotation. The composite inhibitor comprises an organic inhibitor and an inorganic inhibitor, the organic inhibitor is composed of one or two of emodin, chrysophanol, aloe-emodin and rheinic acid, and the inorganic inhibitor is composed of ZnSO4 and any one of CaO, Na2CO3, Na2S2O5 and Ca(ClO)2. Compared with a single inhibitor, the composite inhibitor has the advantages that a complex formed by the composite inhibitor in ore pulp can be adsorbed to the surface of sphalerite, the hydrophilicity of the sphalerite is improved, and the floatability of the sphalerite is reduced. The composite inhibitor can be used in a low-alkalinity environment, can selectively inhibit sphalerite, and basically has no inhibition effect on chalcopyrite; the composite inhibitor is stable in property, small in dosage, safe, non-toxic, easy to add and capable of effectively achieving flotation separation of sphalerite and chalcopyrite.

The invention relates to a composition mixed by parietic acid and berberine, and the composition is used for preventing and treating diabetes and nephropathy and belongs to the medicine field. The composition is characterized in that the mass ratio of parietic acid and berberine is (1:2)-(1:10). A large number of experiments prove that within the mass ratio of 1:2-1:10, the parietic acid and berberine have a synergic effect, and the parietic acid has no side effects like diarrhea, if the mass ratio is not within (1:2)-(1:10) (such as 1 or 2), the parietic acid and berberine have no synergic effect, so that the specific ratio is the key to the composition.

The invention discloses a natural small molecule co-assembled nano-drug delivery system as well as a preparation method and application thereof. The natural small molecule co-assembled nano-drug delivery system is a nano-particle formed by co-assembling two or more than two of oleanolic acid, ursolic acid, glycyrrhetinic acid, betulinic acid, betulin, liquidambaric acid, lupeol, paclitaxel, rheinic acid and catechinic. The original self-assembly morphology of a compound can be changed, nanoparticles with different morphologies and sizes are prepared, and the problem that the morphology of compounds is not suitable for intravenous injection is solved. The nano-drug delivery system disclosed by the invention has one or more pharmacological activities, the compounds forming the nano-drug delivery system play a synergistic anti-tumor role through different mechanisms, and the system has health-care functions and can be used for improving the oxidation resistance of an organism.

The invention discloses a POSS-rheinic acid fluorescent probe for detecting magnesium ions and a preparation method thereof, and belongs to the technical field of chemical detection. The preparation method comprises following steps: dissolving POSS-NH3Cl powder into methanol; making the solution go through an anion resin column to obtain a POSS-NH2 methanol solution; then adding rheinic acid intothe POSS-NH2 methanol solution, carrying out reactions at a room temperature under stirring, until the color of the reaction solution becomes orange from a yellow color; carrying out dialysis by usinga dialysis bag, and after dialysis, using a rotary evaporator to evaporate the solvent to obtain purple powder namely the POSS-rheinic acid fluorescent probe, which has the advantages that the magnesium ion selectivity and sensitivity are high, and the fluorescent probe is environmentally friendly and nontoxic and has a wide application prospect.

The invention relates to a pharmaceutical composition containing total anthraquinone in rheum and total salvianolic acids and a pharmaceutical application thereof. The composition contains total anthraquinone in rheum, total salvianolic acids and / or carthamin, wherein total anthraquinone in rheum can be replaced with rheum emodin and / or rheinic acid; total salvianolic acids can be replaced with salvianolic acid B and / or tanshinol; and carthamin can be replaced with hydroxysafflor yellow A. The composition can also contain chrysophanol and emodin monomethyl ether, or rhubarb polysaccharide, or salvianolic acid A. The composition can be made into a solid, liquid, gaseous or semisolid preparation. Lots of experiments confirm that the pharmaceutical composition can be used in treating kidney disease, hypertensive nephropathy, cardiovascular and cerebrovascular diseases and tumour disease, etc.

The invention relates to a targeting active molecule in a natural product and an application thereof, and in particular relates to a GPR35 receptor new agonist in the natural product and an application thereof. The GPR35 receptor new agonist comprises the active ingredients of one or more than two of compounds of rheinic acid, quercetin, 7-demethylated gingko biflavone, prohypericin, baicalin, tetrahydrodimethoxydibenzoquinoline diol, aloe-emodin, norbodine, daidzein, tanshinone IIA, sweet clover, magnoflorine, cryptotanshinone and isofulvic alcohol and corresponding pharmaceutically acceptable salt forming compounds. In-vitro cell experiments show that natural compounds included in the GPR35 receptor new agonist have an agonistic effect on the GPR35 receptor. At present, researches show that the GPR35 receptor is closely related to asthma, heart failure, hypertension, inflammation, coronary heart disease, metabolic syndrome, pain, cancer and other diseases. The GPR35 receptor novel agonist provides candidate compounds for drug development of the related diseases.

The invention relates to a composition for treating kidney diseases and pharmaceutical application thereof. The composition comprises total anthraquinone composed of 1,3,8-trihydroxy-6-methylanthraquinone and / or rhein (4.5-dihydroxy anthraquinone), an astragalus root extract composed of astragalus polysaccharide and / or astragaloside, and salvianolic acid or carthamin and is applied to treating the kidney diseases and other diseases in a constant reagent quantity. The composition can further comprise 1,8-Dihydroxy-3-methyl-anthraquinone and 1,8-dihydroxy-3-methoxy-6-methylanthraquinone emodin3-methyl ether or calycosin, wherein calycosin-7-glucoside, salvianolic acid B and hydroxysafflor yellow A treat the kidney diseases. The composition can be prepared into a preparation in the form of solid, liquid, gas or semisolid; based on a quantity of experiments, the composition can be used for treating chronic renal failure, nephrotic syndrome, cardiovascular and cerebrovascular diseases, tumorous diseases and the like.

The invention discloses a preparation method and application of a magnetic temperature-sensitive molecularly imprinted polymer based on a deep eutectic solvent system, and belongs to the technical field of functional material preparation. The N-isopropylacrylamide / (3-acrylamidopropyl) trimethyl ammonium chloride eutectic solvent system is used as a functional monomer, so that the adsorption capacity of an imprinted product is improved, and the reusability is relatively high. The molecularly imprinted polymer is used as a dispersive solid-phase extraction adsorbent, and is combined with a high performance liquid chromatography to establish a novel high-selectivity separation and enrichment method for rhein in a semen cassiae sample. In order to further prove the applicability of the molecular imprinting technology, another two magnetic temperature-sensitive molecularly imprinted polymers are prepared by adopting the eutectic solvent system as a functional monomer, and can be used for efficient analysis of triterpenoid saponin compounds and aristolochic acid substances; the application value of the magnetic temperature-sensitive molecularly imprinted polymer based on the eutectic solvent system in complex sample analysis is disclosed.

The invention discloses an ultra-high performance liquid chromatography-diode array method (UPLC-DAD) for simultaneously detecting five anthraquinone compounds (emodin, physcion, chrysophanol, rhein and aloe-emodin) in polygonum multiflorum. The polygonum multiflorum is used as a traditional tonifying medicine and has a long history. The anthraquinone compound is a main natural medicine component in polygonum multiflorum, has the functions of antibiosis, anti-inflammation, immunoregulation and cardiovascular protection, and is mainly composed of emodin, physcion, chrysophanol, rhein and aloe-emodin. According to the method, a dispersive solid-phase extraction (DSPE) method is adopted, a UPLC-DAD analysis technology is combined, a novel analysis method for simultaneously detecting the five anthraquinone compounds in the polygonum multiflorum is provided, the detection limit of an instrument is 0.01-0.07 mg / L, and a technical means is provided for quality control and safety evaluation of the polygonum multiflorum medicinal material.

The invention belongs to the technical field of coatings, and discloses a method and system for preparing an oceanic waterproof and oil-proof ceramic coating on the substrate surface. The preparing system comprises a preparing module, a liquid preparing module, a powder preparing module, a reacting module, a stirring module, a mixing module and a grinding module. Rumex japonicus meisn in the ceramic coating comprises effective constituents of the chrysophanol, the emodin and the chrysophanic acid, and has the remarkable inhibiting effect on bacteria; the effect of the effective constituents isbetter developed through extraction, and latex has the good antibacterial ability, and can lock effective constituents of the rumex japonicus meisn extract; meanwhile, raw materials of the water proof coating adopt liquid and powder, the making difficulty of the coating can be greatly reduced, the cost required by production of the coating can be greatly reduced, and production is convenient.

The present invention relates to the process for the preparation of topical formulations of anthraquinone compound. The present invention specifically relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of ointment, cream, gel and transferosomal gel. The present invention more specifically relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of ointment, cream, gel comprising the steps of heating, adding, stirring, dissolving and mixing. The present invention also relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of transferosomal gel comprising the steps of thin film formation, hydration of thin film and transferosomal gel formation. The present invention also relates to the process for the preparation of topical formulations of Rhein or Diacerein in the form of transferosomal gel comprising the steps of dissolving, adding and mixing.

A compound with anti-drug resistant bacteria activity having the following formulais disclosed. A method of preparing the compound of formula (I) is also disclosed.

The invention relates to a mass control method for a medicinal composition for treating hepatitis, in particular to a mass control method for a Jiuwei glucurolactone traditional Chinese medicine. The method comprises the following steps of: authenticating thin-layer chromatography of pseudo-ginseng, rheum officinale and scutellaria baicalensis, namely measuring total content of rheum emodin (C15H10O5) and chrysophanic acid (C15H10O4) by high performance liquid chromatography; and authenticating schisandra chinensis, namely checking rhaponticin and measuring the schizandrin content. By the method, a schisandra chinensis thin-layer authentication control method and a schizandrin content extreme control method are added; and a rhaponticin checking step is added, so that false rheum officinale can be prevented from being mixed into the medicine.

The present invention provides a TPGS-modified carboxymethyl chitosan-rhein conjugate as shown in formula I, wherein A and B are independently selected from rhein or TPGS; n=436-512. The invention also provides the synthesis process of the conjugate and the application of the conjugate in the preparation of drug-loaded micelles. The TPGS modified carboxymethyl chitosan-rhein conjugate prepared by the present invention can self-assemble into micelles in water; the micelles have a very high drug loading capacity for paclitaxel, and the particle size is small; significantly promote paclitaxel in the stomach Intestinal absorption; the drug-loaded micelles have significant anti-tumor effects, can inhibit the drug-resistant effects of tumors, and have less toxic and side effects.

In view of difficulty in clinical administration of rhein, the invention firstly provides a rhein phospholipid complex as well as a preparation method and application thereof. The preparation method of the rhein phospholipid complex includes the following steps: (1) weighing rhein and a first phospholipid according to the weight ratio of the rhein to the first phospholipid of 2:1 to 1:20, and dispersing the weighed rhein and first phospholipid in an organic solvent to obtain a reaction solution; (2) performing a reaction on the reaction solution under stirring at 30-60 DEG C for 2-24 h; and (3) performing reduced-pressure concentration on the solution after the reaction, and collecting the obtained solid to obtain the rhein phospholipid complex; and preparing a long-circulating liposome by using the rhein phospholipid complex, a second phospholipid, cholesterol, and distearoyl phosphatidylethanolamine-polyethylene glycol. According to the preparation method provided by the invention,after the rhein is compounded with the phospholipid, the solubility is improved, the druggability is improved, preparation of preparations is facilitated, and the complex is used to further prepare the long-circulating liposome, so that the biological half-life period of the rhein is effectively prolonged while efficient drug loading capacity is ensured.